» Articles » PMID: 21459938

Quantitative Data for Care of Patients with Systemic Lupus Erythematosus in Usual Clinical Settings: a Patient Multidimensional Health Assessment Questionnaire and Physician Estimate of Noninflammatory Symptoms

Overview
Journal J Rheumatol
Specialty Rheumatology
Date 2011 Apr 5
PMID 21459938
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To analyze quantitative data in patients with systemic lupus erythematosus (SLE), seen in usual care, from a patient Multidimensional Health Assessment Questionnaire (MDHAQ) with routine assessment of patient index data (RAPID3) scores and from a physician global estimate of noninflammatory symptoms; and to compare results to self-report Systemic Lupus Activity Questionnaire (SLAQ) scores and 4 SLE indices: SLE Disease Activity Index-2K (SLEDAI-2K), British Isles Lupus Assessment Group (BILAG), Systemic Lupus Activity Measure (SLAM), and European Consensus Lupus Activity Measurement (ECLAM).

Methods: Fifty consecutive patients with SLE were studied in usual care of one rheumatologist. All patients completed an MDHAQ/RAPID3 in this setting. Each patient also completed a SLAQ. The rheumatologist scored SLEDAI-2K, BILAG, SLAM, ECLAM, and 2 physician global estimates, one for overall status and one for noninflammatory symptoms. Patients were classified into 2 groups: "few" or "many" noninflammatory symptoms. Scores and indices were compared using correlations, cross-tabulations and t tests.

Results: The patients included 45 women and 5 men. MDHAQ/RAPID3 and SLAQ scores were significantly correlated. RAPID3 scores were significantly higher in patients with SLE index scores above median levels, and in 34 patients scored by the rheumatologist as having "few" noninflammatory symptoms. MDHAQ/RAPID3 and SLAQ were significantly higher in 16 patients scored as having many noninflammatory symptoms.

Conclusion: MDHAQ/RAPID3 and SLAQ subscale scores appear to reflect disease activity in patients with SLE, but not in patients with many noninflammatory symptoms. A physician scale for noninflammatory symptoms is useful to interpret MDHAQ/RAPID3, SLAQ, and SLE index scores.

Citing Articles

Evaluating the real-world effectiveness of belimumab in patients with SLE using SLE-related laboratory values and rheumatoid arthritis-derived disease activity measures: RAPID3, swollen joint count and tender joint count.

Germain G, Worley K, MacKnight S, Rubin B, Bell C, Laliberte F Lupus Sci Med. 2024; 11(1).

PMID: 38575172 PMC: 11002435. DOI: 10.1136/lupus-2023-001111.


Medication Cost Concerns and Disparities in Patient-Reported Outcomes Among a Multiethnic Cohort of Patients With Systemic Lupus Erythematosus.

Aguirre A, DeQuattro K, Shiboski S, Katz P, Greenlund K, Barbour K J Rheumatol. 2023; 50(10):1302-1309.

PMID: 37321640 PMC: 10543599. DOI: 10.3899/jrheum.2023-0060.


Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE.

Askanase A, Tang W, Zuraw Q, Gordon R, Brotherton B, Merrill J Lupus Sci Med. 2023; 10(1).

PMID: 37012059 PMC: 10083883. DOI: 10.1136/lupus-2022-000875.


A 5-Year Retrospective, Observational Study Assessing Rheumatoid Arthritis Disease Outcome Measures to Characterize Systemic Lupus Erythematosus Burden in the USA.

Bell C, Huang S, Yu L, DerSarkissian M, Germain G, Concoff A Rheumatol Ther. 2022; 10(1):261-274.

PMID: 36471198 PMC: 9931978. DOI: 10.1007/s40744-022-00509-x.


Patient-Reported Outcomes for Quality of Life in SLE: Essential in Clinical Trials and Ready for Routine Care.

Nguyen M, Huang F, ONeill S J Clin Med. 2021; 10(16).

PMID: 34442047 PMC: 8396817. DOI: 10.3390/jcm10163754.